Cited by 235Glioma Diagnosis and TreatmentCancer Genomics and DiagnosticsCancer-related Molecular Pathways

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Genetic pathways to glioblastomas

Ohgaki, Hiroko·2005·Neuropathology

DOI 10.1111/j.1440-1789.2004.00600.x

Open this paper in CoChat — free account

Abstract

Glioblastomas, the most frequent and malignant human brain tumors, may develop de novo (primary glioblastoma) or by progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). These glioblastoma subtypes constitute distinct disease entities that affect patients of different ages and develop through different genetic pathways. Our recent population-based study in the Canton of Zürich, Switzerland, shows that primary glioblastomas develop in older patients (mean age, 62 years) and typically show LOH on chromosome 10q (69%) and other genetic alterations (EGFR amplification, TP53 mutations, p16INK4a deletion, and PTEN mutations) at frequencies of 24-34%. Secondary glioblastomas develop in younger patients (mean, 45 years) and frequently show TP53 mutations (65%) and LOH 10q (63%). Common to both primary and secondary glioblastoma is LOH on 10q, distal to the PTEN locus; a putative suppressor gene at 10q25-qter may be responsible for the glioblastoma phenotype. Of the TP53 point mutations in secondary glioblastomas, 57% were located in hotspot codons 248 and 273, while in primary glioblastomas, mutations were more widely distributed. Furthermore, G:C-->A:T mutations at CpG sites were more frequent in secondary than in primary glioblastomas (56% vs 30%). These data suggest that the TP53 mutations in these glioblastoma subtypes arise through different mechanisms. There is evidence that G:C-->A:T transition mutations at CpG sites in the TP53 gene are significantly more frequent in low-grade astrocytomas with promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene than in those without methylation. This suggests that, in addition to deamination of 5-methylcytosine (the best known mechanism of formation of G:C-->A:T transitions at CpG sites), involvement of alkylating agents that produce O6-methylguanine or related adducts recognized by MGMT cannot be excluded in the pathway leading to secondary glioblastomas.

Integrity signals

Registry

Crossref · 10.1111/j.1440-1789.2004.00600.x

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Patre, P.-L. D., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,306
Self-citation
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials
Stewart, L. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08091-1 · Cited by 1,232
The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2
Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K. M., Hara, E., Vousden, K. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,178
Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis
Ohshima, H., & Bartsch, H. (1994) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(94)90245-3 · Cited by 1,050
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 739
Self-citation
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663

Show all 64 references

Research works printed but not linked: 1

Kleihues P, 2000, WHO Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System.

Sorted by citations

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 565
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents
Reardon, D. A., & Wen, P. Y. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-152 · Cited by 233
Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
Zohrabian, V. M., Forzani, B., Chau, Z., Murali, R., & Jhanwar‐Uniyal, M. (2009) · PubMed · Cited by 177
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
Dresemann, G. P. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi317 · Cited by 173
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 174
Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival
Eoli, M., Menghi, F., Bruzzone, M. G., Simone, T. D., Valletta, L., Pollo, B., Bissola, L., Silvani, A., Bianchessi, D., D’Incerti, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2184 · Cited by 158
Glioblastoma Multiforme Oncogenomics and Signaling Pathways
Kanu, O. O., Hughes, B. D., Di, C., Lin, N., Fu, J., Bigner, D. D., Yan, H., & Adamson, C. (2009) · Clinical medicine Oncology · doi:10.4137/cmo.s1008 · Cited by 146
Rational bases for the development of EGFR inhibitors for cancer treatment
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.05.008 · Cited by 144
microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma
Ling, N., Gu, J., Lei, Z., Li, M., Zhao, J., Zhang, H., & Li, X. (2013) · Oncology Reports · doi:10.3892/or.2013.2685 · Cited by 125
Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3
Yang, F., Brown, C. E., Buettner, R., Hedvat, M., Starr, R., Scuto, A., Schroeder, A., Jensen, M. C., & Jove, R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0947 · Cited by 121
Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.019 · Cited by 114
Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation
Maru, S., Holloway, K., Flynn, G., Lancashire, C. L., Loughlin, J., Male, D. K., & Romero, I. A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.04.029 · Cited by 121
MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival
Demuth, T., Reavie, L. B., Rennert, J. L., Nakada, M., Nakada, S., Hoelzinger, D. B., Beaudry, C. E., Henrichs, A. N., Anderson, E., & Berens, M. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0711 · Cited by 114
Cancer stem cells and “stemness” genes in neuro-oncology
Nicolis, S. K. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.022 · Cited by 113
Reciprocal Regulation of SOCS 1 and SOCS3 Enhances Resistance to Ionizing Radiation in Glioblastoma Multiforme
Zhou, H., Miki, R., Eeva, M., Fike, F. M., Seligson, D. B., Yang, L., Yoshimura, A., Teitell, M. A., Jamieson, C., & Cacalano, N. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2303 · Cited by 109
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas
Deshmukh, H., Yeh, T., Yu, J., Sharma, M. K., Perry, A., Leonard, J. R., Watson, M. A., Gutmann, D. H., & Nagarajan, R. (2008) · Oncogene · doi:10.1038/onc.2008.110 · Cited by 107
Gene expressions of TRP channels in glioblastoma multiforme and relation with survival
Alptekin, M., Eroğlu, S., Tutar, E., Şencan, S., GEYİK, M., Ulaşlı, M., Demiryürek, A. T., & Camcı, C. (2015) · Tumor Biology · doi:10.1007/s13277-015-3577-x · Cited by 104
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme—Role in Pathogenesis and Therapeutic Perspective
Pawłowska, E., Szczepańska, J., Szatkowska, M., & Błasiak, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030889 · Cited by 100
Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by β8 Integrin
Tchaicha, J. H., Reyes, S. B., Shin, J., Hossain, M. G., Lang, F. F., & McCarty, J. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0991 · Cited by 95
Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review)
Zhang, X., Zhang, W., Cao, W., Cheng, G., & Zhang, Y. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.367 · Cited by 93
Osteopontin regulates human glioma cell invasiveness and tumor growth in mice
Jan, H.-J., Lee, C.-C., Shih, Y., Hueng, D., Ma, H.-I., Lai, J.-H., Wei, H., & Lee, H.-M. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop013 · Cited by 89
The brominated flame retardant BDE-47 causes oxidative stress and apoptotic cell death in vitro and in vivo in mice
Costa, L. G., Pellacani, C., Dao, K., Kavanagh, T. J., & Roqué, P. J. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.03.008 · Cited by 83
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1
Huttner, A. J., Kieran, M. W., Yao, X., Cruz, L., Ladner, J., Quayle, K., Goumnerova, L. C., Irons, M., & Ullrich, N. J. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22462 · Cited by 82
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms
Otero, J. J., Rowitch, D. H., & VandenBerg, S. R. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0509-x · Cited by 80
Molecular signatures classify astrocytic gliomas by IDH1 mutation status
Toedt, G., Barbus, S., Wolter, M., Felsberg, J., Tews, B., Blond, F., Sabel, M., Hofmann, S., Becker, N., Hartmann, C. J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25448 · Cited by 78
Self-citation
Biology, genetics and imaging of glial cell tumours
Walker, C. A., Baborie, A., Crooks, D. A., Wilkins, S., & Jenkinson, M. D. (2011) · British Journal of Radiology · doi:10.1259/bjr/23430927 · Cited by 78
SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data
Chen, J., Wang, Z., Wang, W., Ren, S., Jinbiao, X., Zhong, L., Jiang, T., Wei, H., & Zhang, C. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106490 · Cited by 76
Ariadne's ChemEffect and Pathway Studio knowledge base
Yuryev, A., Kotelnikova, E. A., & Daraselia, N. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903413488 · Cited by 72
COMPUTATIONAL APPROACHES FOR DRUG REPOSITIONING AND COMBINATION THERAPY DESIGN
Kotelnikova, E. A., Yuryev, A., Mazo, I. A., & Daraselia, N. (2010) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720010004732 · Cited by 69
Feature-Guided Deep Radiomics for Glioblastoma Patient Survival Prediction
Shboul, Z. A., Alam, M., Vidyaratne, L., Pei, L., Elbakary, M. I., & Iftekharuddin, K. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00966 · Cited by 65
Stem cell protein BMI‐1 is an independent marker for poor prognosis in oligodendroglial tumours
Häyry, V., Tynninen, O., Haapasalo, H., Wölfer, J., Paulus, W., Hasselblatt, M., Sariola, H. V., Paetau, A. E., Sarna, S. J., Niemela, M. R., et al. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00949.x · Cited by 65
Angiogenesis and Anti-Angiogenic Molecularly Targeted Therapies in Malignant Gliomas
Argyriou, A. A., Giannopoulou, E., & Kalofonos, H. P. (2009) · Oncology · doi:10.1159/000218165 · Cited by 61
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas
Keßler, R., Bleichert, F., Warnke, J., & Eschrich, K. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9471-7 · Cited by 62
Glioblastoma Inhibition by Cell Surface Immunoglobulin Protein EWI-2, In Vitro and In Vivo
Kolesnikova, T. V., Kazarov, A. R., Lemieux, M. E., Lafleur, M. A., Kesari, S., Kung, A. L., & Hemler, M. E. (2009) · Neoplasia · doi:10.1593/neo.81180 · Cited by 57
Epidermal growth factor receptor and DNA double strand break repair: The cell's self-defence
Szumiel, I. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.03.010 · Cited by 58
Variable Deficiencies in the Interferon Response Enhance Susceptibility to Vesicular Stomatitis Virus Oncolytic Actions in Glioblastoma Cells but Not in Normal Human Glial Cells
Wollmann, G., Robek, M. D., & van den Pol, A. N. (2006) · Journal of Virology · doi:10.1128/jvi.01861-06 · Cited by 55
Downregulation of PIK3CB by siRNA Suppresses Malignant Glioma Cell Growth In Vitro and In Vivo
Pu, P., Kang, C., Zhang, Z., Liu, X., & Jiang, H. (2006) · Technology in Cancer Research & Treatment · doi:10.1177/153303460600500308 · Cited by 54
Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma
Gandini, N. A., Fermento, M. E., Salomón, D. G., Obiol, D. J., Andrés, N. C., Zenklusen, J. C., Arévalo, J., Blasco, J., Romero, A. L., Facchinetti, M. M., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-1373-z · Cited by 53
Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches
Alexandru, O., Horescu, C., Sevastre, A.-S., Cioc, C. E., Baloi, C., Oprița, A., & Dricu, A. (2020) · Współczesna Onkologia · doi:10.5114/wo.2020.94726 · Cited by 53
The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme
Wang, E., Zhang, C., Polavaram, N. S., Liu, F., Wu, G., Schroeder, M. A., Lau, J. S., Mukhopadhyay, D., Jiang, S., O’Neill, B. P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086102 · Cited by 49
Revisiting the role of p53 in primary and secondary glioblastomas.
(2006) · PubMed · Cited by 51
Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism
Lin, Y., Jan, H.-J., Lee, C.-C., Tao, H.-Y., Shih, Y., Wei, H., & Lee, H.-M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.111 · Cited by 50
Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas
Li, J. Y., Wang, H., May, S., Song, X., Fueyo, J., Fuller, G. N., & Wang, H. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9529-1 · Cited by 48
Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas
Kim, Y., Cho, Y. S., Kim, Y. W., Kim, J., Lee, S. H., & Park, J. (2008) · The Journal of Pathology · doi:10.1002/path.2401 · Cited by 47
Low-Grade Gliomas
Ruiz, J., & Lesser, G. J. (2009) · Current Treatment Options in Oncology · doi:10.1007/s11864-009-0096-2 · Cited by 46
Bioinformatics analysis reveals disturbance mechanism of MAPK signaling pathway and cell cycle in Glioblastoma multiforme
Li, W., Li, K., Zhao, L., & Zou, H. (2014) · Gene · doi:10.1016/j.gene.2014.06.042 · Cited by 44
Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection
Suchorska, B., Ruge, M. I., Treuer, H., Sturm, V., & Voges, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor100 · Cited by 43
Photodynamic process induced by chloro-aluminum phthalocyanine nanoemulsion in glioblastoma
Castilho–Fernandes, A., Lopes, T. G., Primo, F. L., Pinto, M. R., & Tedesco, A. C. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.05.003 · Cited by 43
The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFRamplification
López‐Ginés, C., Gil‐Benso, R., Benito, R., Mata, M., Pereda, J., Sastre, J., Roldán, P., Gonzalez-Darder, J. M., & Cerdá‐Nicolás, M. (2008) · Neuropathology · doi:10.1111/j.1440-1789.2008.00911.x · Cited by 43
Bacterial Carriers for Glioblastoma Therapy
Mehta, N., Lyon, J. G., Patil, K., Mokarram, N., Kim, C. G., & Bellamkonda, R. V. (2016) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.12.003 · Cited by 41
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Patties, I., Kallendrusch, S., Böhme, L., Kendzia, E., Oppermann, H., Gaunitz, F., Kortmann, R., & Glasow, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1434-2 · Cited by 42
Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients
Su, J., Guo, B., Zhang, T., Wang, K., Li, X., & Liang, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-3319-0 · Cited by 40
Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme
Salomón, D. G., Fermento, M. E., Gandini, N. A., Ferronato, M. J., Arévalo, J., Blasco, J., Andrés, N. C., Zenklusen, J. C., Curino, A. C., & Facchinetti, M. M. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1416-3 · Cited by 40
Biology of Glioblastoma Multiforme—Exploration of Mitotic Catastrophe as a Potential Treatment Modality
Vítovcová, B., Skarková, V., Rudolf, K., & Rudolf, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155324 · Cited by 40
Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)
Atat, O. E., Naser, R., Abdelkhalek, M., Abi‐Habib, R. J., & El‐Sibai, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13632 · Cited by 40
Overexpression of S6 Kinase 1 in Brain Tumours Is Associated with Induction of Hypoxia-Responsive Genes and Predicts Patients' Survival
Ismail, H. M. (2012) · Journal of Oncology · doi:10.1155/2012/416927 · Cited by 39
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Siker, M., Chakravarti, A., & Mehta, M. P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.04.005 · Cited by 36
ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas
Fan, X., Wang, Y., Zhang, C., Liu, L., Yang, S., Wang, Y., Liu, X., Qian, Z., Fang, S., Qiao, H., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091276 · Cited by 36
Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cells
Horibe, T., Torisawa, A., Kohno, M., & Kawakami, K. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-59 · Cited by 35
PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway
Desai, S., Pillai, P., Win-Piazza, H., & Acevedo-Duncan, M. E. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.007 · Cited by 36
Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy
Barajas, R., & Cha, S. (2014) · CNS Oncology · doi:10.2217/cns.14.44 · Cited by 35
Expression and putative functions of GDF-15, a member of the TGF-β superfamily, in human glioma and glioblastoma cell lines
Strelau, J., Schmeer, C., Peterziel, H., Sackmann, T., Herold‐Mende, C. C., Steiner, H. H., Weller, M., & Unsicker, K. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.042 · Cited by 35
Engineered smart materials for RNA based molecular therapy to treat Glioblastoma
Singh, R. R., Mondal, I., Janjua, T. I., Popat, A., & Kulshreshtha, R. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.007 · Cited by 36
Molecularly Targeted Therapies for Malignant Gliomas
Argyriou, A. A., & Kalofonos, H. P. (2009) · Molecular Medicine · doi:10.2119/molmed.2008.00123 · Cited by 34
Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
Degrauwe, N., Sosa, J. A., Roman, S. A., & Deshpande, H. A. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7999 · Cited by 34
Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas
Liu, J., Lu, H., Ohgaki, H., Merlo, A. U., & Shen, Z. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-268 · Cited by 33
Self-citation
Altered expression of alpha-dystroglycan subunit in human gliomas
Calogero, A., Pavoni, E., Gramaglia, T., d’Amati, G., Ragona, G., Brancaccio, A., & Petrucci, T. C. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.4.2546 · Cited by 33
Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low DNA Content
Milbury, C. A., Chen, C. C., Mamon, H. J., Liu, P., Santagata, S., & Makrigiorgos, G. M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.008 · Cited by 33
Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies
Argyriou, A. A., Antonacopoulou, A. G., Iconomou, G., & Kalofonos, H. P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.05.005 · Cited by 33
Effect of Combination Treatment of Rapamycin and Isoflavones on mTOR Pathway in Human Glioblastoma (U87) Cells
Puli, S., Jain, A., Lai, J. C. K., & Bhushan, A. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0142-2 · Cited by 33
RNA interference therapy for glioblastoma
Guo, D., Wang, B., Han, F., & Lei, T. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481667 · Cited by 33
Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFκB activation in glioblastoma
Kuwayama, K., Matsuzaki, K., Mizobuchi, Y., Mure, H., Kitazato, K. T., Kageji, T., Nakao, M., & Nagahiro, S. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-083 · Cited by 31
Aging and Neurological Diseases
Kowalska, M., Owecki, M. K., Prendecki, M., Wize, K., Nowakowska, J., Kozubski, W. P., Lianeri, M., & Dorszewska, J. (2017) · InTech eBooks · doi:10.5772/intechopen.69499 · Cited by 31
The future role of personalized medicine in the treatment of glioblastoma multiforme
Adamson, C. (2010) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6852 · Cited by 32
High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations
Jesień-Lewandowicz, E., Jesionek‐Kupnicka, D., Zawlik, I., Szybka, M., Kulczycka-Wojdala, D., Rieske, P., Sieruta, M., Jaskólski, D. J., Och, W., Skowroński, W., et al. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.09.015 · Cited by 31
Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines
Godoy, P. R. D. V., Mello, S. S., Magalhães, D. A. R., Donaires, F. S., Nicolucci, P., Donadi, E. A., Passos, G. A. S., & Sakamoto‐Hojo, E. T. (2013) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2013.06.010 · Cited by 30
Methods for Analysis of Brain Tumor Stem Cell and Neural Stem Cell Self-Renewal
Nakano, I., & Kornblum, H. I. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-280-9_4 · Cited by 30
Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools
Valdebenito, S., Damico, D. C. S., & Eugenín, E. A. (2019) · Cancer Reports · doi:10.1002/cnr2.1220 · Cited by 29
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Mason, W. P., & Cairncross, J. G. (2008) · Neurology · doi:10.1212/01.wnl.0000319721.98502.1b · Cited by 29
EGFR-targeting agents in oncology
Garofalo, S., Rosa, R., Bianco, R., & Tortora, G. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.889 · Cited by 29
Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications.
Brown, R. E., & Law, A. (2006) · PubMed · Cited by 29
Immunohistochemical Classification of Primary and Secondary Glioblastomas
Lee, K. S., Choe, G., Nam, K. H., Seo, A. N., Yun, S., Kim, K. J., Cho, H. J., & Park, S. (2013) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2013.47.6.541 · Cited by 29
Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC- -mediated signaling cascade in glioblastoma
Desai, S. R., Pillai, P. P., Patel, R. S., McCray, A. N., Win-Piazza, H., & Acevedo-Duncan, M. E. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr231 · Cited by 28
Effect of Rosehip (Rosa Canina) Extracts on Human Brain Tumor Cell Proliferation and Apoptosis
Cagle, P., Idassi, O. M., Carpenter, J., Minor, R. C., Goktepe, I., & Martin, P. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.35069 · Cited by 27
Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma
Payne, C. A., Maleki, S., Messina, M., O’Sullivan, M. G., Stone, G., Hall, N. R., Parkinson, J., Wheeler, H., Cook, R., Biggs, M. T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0629 · Cited by 27
Imaging Genomics in Gliomas
Zinn, P. O., Mahmood, Z., Elbanan, M., & Colen, R. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000120 · Cited by 26
Analysis of the polymorphisms XRCC1Arg194Trp and XRCC1Arg399Gln in gliomas
Custódio, A. C., Almeida, L. O., Pinto, G. R., Santos, M. J., Almeida, J. R. W., Clara, C., Rey, J. A., & Casartelli, C. (2011) · Genetics and Molecular Research · doi:10.4238/vol10-2gmr1125 · Cited by 24
Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis in Human Glioblastoma Cells
Pal, D., Mukhopadhyay, D., Ramaiah, M. J., Sarma, P. N., Bhadra, U., & Bhadra, M. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159092 · Cited by 25
Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil
Koshiyama, D. B., Trevisan, P., Graziadio, C., Rosa, R. F. M., Cunegatto, B., Scholl, J. N., Provenzi, V. O., de Sá, A., Soares, F. P., Velho, M. C., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2606-6 · Cited by 25
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Leonetti, C., Biroccio, A., Graziani, G., & Tentori, L. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277403 · Cited by 25
Coordination of glioblastoma cell motility by PKCι
Baldwin, R. M., Barrett, G. M., Parolin, D. A., Gillies, J. K., Paget, J., Lavictoire, S. J., Gray, D., & Lorimer, I. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-233 · Cited by 29
p85α promotes nucleolin transcription and subsequently enhances EGFR mRNA stability and EGF-induced malignant cellular transformation
Xie, Q., Guo, X., Gu, J., Zhang, L., Jin, H., Huang, H., Li, J., & Huang, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7674 · Cited by 26
Variation in DNA repair gene XRCC3 affects susceptibility to astrocytomas and glioblastomas
Custódio, A. C., Almeida, L. O., Pinto, G. R., dos Santos, M. J., Almeida, J. R. W., Clara, C., REY, J. A., & Casartelli, C. (2012) · Genetics and Molecular Research · doi:10.4238/2012.february.10.4 · Cited by 24
E2F transcription factors associated with up-regulated genes in glioblastoma
Donaires, F. S., Godoy, P. R. D. V., Leandro, G. D. S., Puthier, D., & Sakamoto‐Hojo, E. T. (2016) · Cancer Biomarkers · doi:10.3233/cbm-161628 · Cited by 24
Radiation‐induced glioblastoma in a medulloblastoma patient: A case report with molecular features
Gessi, M., Maderna, E., Guzzetti, S., Cefalo, G., Massimino, M., Solero, C. L., Finocchiaro, G., & Pollo, B. (2008) · Neuropathology · doi:10.1111/j.1440-1789.2008.00900.x · Cited by 24
Potential CanonicalWntPathway Activation in High-Grade Astrocytomas
Schüle, R., Dictus, C., Campos, B., Wan, F., Felsberg, J., Ahmadi, R., Centner, F.-S., Grabe, N., Reifenberger, G., Bermejo, J. L., et al. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/697313 · Cited by 23
Therapeutic Evaluation of microRNAs by Molecular Imaging
Sekar, T. V., Ramkumar, K. M., Foygel, K., & Paulmurugan, R. (2013) · Theranostics · doi:10.7150/thno.4928 · Cited by 23
VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME
Simon, M., Ludwig, M., Fimmers, R., Mahlberg, R., Erkwoh, A., Köster, G., & Schramm, J. (2006) · Neurosurgery · doi:10.1227/01.neu.0000245590.08463.5b · Cited by 24

Authors: Ohgaki, H.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Ohgaki, Hiroko
Venue: Neuropathology
Publisher: Wiley
Published: 2005-02-28
Volume: 25
Issue: 1
Pages: 1-7
ISSN: 0919-6544 (ISSN-L)
1440-1789
DOI: 10.1111/j.1440-1789.2004.00600.x
OpenAlex: W2097876071
Cited by: 235
References: 64
Citations by year: 2026: 4 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 8 · 2019: 8 · 2018: 7 · 2017: 6 · 2016: 14 · 2015: 8 · 2014: 12 · 2013: 11 · 2012: 11
FWCI: 3.08
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Neuropathology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: glioblastoma, primary glioblastoma, secondary glioblastoma, low-grade astrocytoma, anaplastic astrocytoma, tumor progression, TP53 mutation, promoter methylation, MGMT, alkylating agents, EGFR amplification, PTEN mutation, suppressor genes, gene pathways
MeSH terms: Age Factors, Brain Neoplasms, Glioblastoma, Humans, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genetic pathways to glioblastomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks